This technology includes the clinical use of the small compound emetine for the treatment of SARS-CoV-2. Previous work has shown that emetine has antiviral properties against some DNA and RNA viruses. It is thought that the mechanism may involve blocking protein synthesis. Work has shown that emetine has potential antiviral activity in multiple tissues that may make it suitable for the treatment of COVID-19.
Further clinical work may establish emetine as a therapeutic for SARS-CoV-2.
There are no current approved therapies for SARS-CoV-2 infection.